Recent News

• 03.11.2025 - Labcorp Announces Acquisition of Select Assets of BioReference Health’s Innovative Oncology and Related Clinical Testing Services Businesses
• 02.27.2025 - OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results
• 02.27.2025 - OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results
• 02.13.2025 - OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025
• 02.13.2025 - OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025
• 01.09.2025 - OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference
• 01.09.2025 - OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference
• 01.07.2025 - OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck
• 01.07.2025 - OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck

Recent Filings

• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - EX-99.1 EX-99.1
• 02.27.2025 - 8-K Current report
• 01.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.15.2025 - EX-99.1 EX-99.1